Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China flag China · Delayed Price · Currency is CNY
25.85
+0.94 (3.77%)
At close: Mar 6, 2026
Market Cap12.35B +258.5%
Revenue (ttm)244.37M -30.3%
Net Income-166.17M
EPS-0.32
Shares Out477.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,907,240
Average Volume16,913,585
Open24.76
Previous Close24.91
Day's Range24.76 - 26.17
52-Week Range5.90 - 66.66
Beta0.99
RSI45.80
Earnings DateMar 24, 2026

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release ta... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 484
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300204
Full Company Profile

Financial Performance

In 2024, SHE:300204's revenue was 324.82 million, a decrease of -10.81% compared to the previous year's 364.18 million. Losses were -144.84 million, -63.69% less than in 2023.

Financial Statements